Category Archives: Parkinson’s Treatment

LONDON Having become popular with both celebrities and investors, diabetes drugs that also promote weight loss, such as Novo Nordisks Ozempic, are now being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimers disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose use and tamping down inflammation in the entire body including the brain could slow progression of debilitating diseases like Alzheimer's and Parkinson's Continue reading →

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights. In the first quarter, we continued to make significant progress across our broad therapeutic portfolio, including the advancement of multiple late-stage programs, said Ryan Watts, Ph.D., Chief Executive Officer at Denali Continue reading →

Prothena Co. plc (NASDAQ:PRTA) has been in the headlines lately due to its fluctuating stock ratings and earnings reports. According to a recent report by Bloomberg.com, the biotechnology company has received an average rating of Moderate Buy from twelve analysts covering the firm Continue reading →

Untrained listeners who are crowdsourced to assess voice treatment for people with Parkinsons can reach conclusions that agree with reliable measurement tools, finds a team of speech-language pathology researchers. Studies of speech and voice treatment methods for individuals with Parkinsons Disease typically evaluate progress using fine-grained acoustic measures or highly trained listeners perceptual ratings, says lead author Tara McAllister, NYU Steinhardt Associate Professor. However, this approach leaves some uncertainty about the real-world impact of these changes, since it is not always clear they would be apparent to untrained listeners that patients interact with in their daily life Continue reading →

A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics investigational therapy for Parkinsons disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in people with Parkinsons a trial thats part of its so-called 201 program and has shared the new data with the U.S Continue reading →

People with Parkinsons disease given deep brain stimulation (DBS) targeting the right side of the brain experienced fewer cognitive side effects following treatment compared with those who received the procedure to the left side of the brain, according to new findings from a clinical trial. Deep brain stimulation, commonly called DBS, is a surgical treatment for Parkinsons that involves implanting an electrode into the brain to deliver gentle electrical stimulation to specific brain regions. Continue reading →

Physical Therapy for Parkinsons Disease Physical therapy and exercise are crucial aspects of Parkinsons disease (PD) treatment and APDA has many ways to help you get up and moving. Many people are curious about why exercise is so important for someone with PD and what type of exercise is best for someone with PD, which weve talked about in earlier programs and blog posts. This previous Q+A session also addresses the best way to approach exercise and PD. Continue reading →

Christine Lebrun-Frenay, MD, PhD, FAAN Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, findings from the phase 3 TERIS study (NCT03122652) showed that treatment with teriflunomide (Aubagio; Sanofi) significantly reduced the time to first clinical event in patients with radiologically isolated syndrome (RIS), often considered the presymptomatic phase of multiple sclerosis (MS). Continue reading →

Newswise In Srmland, Sweden, music therapy is offered as a method of treatment for people living with chronic pain. Currently, the effects of what is known as the FMT method are being investigated through a research project at Mlardalen University (MDU) Continue reading →

The Global Parkinson's Disease Treatments market research report 2023 provides an in-depth analysis of an industry or market, covering essential aspects such as market size, growth potential, competitive landscape, consumer behaviour, and other significant factors influencing the market. This report is a valuable resource for businesses seeking to enter or expand their presence in the market, as it enables them to make informed strategic decisions. Continue reading →